Advertisement

Topics

Eli Lilly’s lasmiditan meets Phase III trial endpoints for migraine

19:00 EDT 6 Aug 2017 | Net Resources International

Eli Lilly and Company has reported positive results from the Phase III SPARTAN clinical trial of lasmiditan for the acute treatment of migraines.

Original Article: Eli Lilly’s lasmiditan meets Phase III trial endpoints for migraine

NEXT ARTICLE

More From BioPortfolio on "Eli Lilly’s lasmiditan meets Phase III trial endpoints for migraine"

Quick Search
Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...